463:
89.6% received surgical treatment, 29.2% received radiation treatment, and 20% received chemotherapy. The study concluded that radiotherapy and chemotherapy had limited effects on survival and therefore should not be routinely used in LGMS, especially for cases in which all tumor cells are removed. These results and conclusions agree with previous reports finding that LGMS tumors are insensitive to radiotherapy and chemotherapy. Nonetheless, there have been case reports that local radiotherapy may allow longer survival periods and may, in select cases, be useful for treating LGMS. A similar situation exists with chemotherapy: some reports recommend chemotherapy as a potential treatment strategy, particularly when complete excision of the tumor is not possible, when the tumor is highly invasive, and/or when the tumor has spread to lymph nodes and/or distant tissues. There are case reports where chemotherapy following surgical excision may have been useful in prolonging progression-free survival, for example, in an individual with a pancreatic LGMS tumor (treatment regimen:
479:
75.0% and 71.6%, respectively. Their disease-specific survival (i.e. excluding deaths from causes unrelated to LGMS) at 3 and 5 years after treatment were 80.0% and 76.3%, respectively. These patients were treated with surgery in 93.9% of cases and radiotherapy in 26.5% of cases but no patients had lymph node metastasis and only 1 case had distant metastases (the presence of lymph node and distant tissue metastasis was unknown in 8 patients). The study of 96 individuals treated for LFMS reported 1, 3, 5, and 10-year disease-specific survival percentages of 88%, 77%, 70%, and 59%, respectively. Patient age >60 years was the only factor that clearly reduced survival times in this study (disease specific survival times for patients 60 years old or younger and >60 years were 167.1 and 92.5 months, respectively).
452:, have not been systematically investigated nor validated. Currently, the primary and most common treatment for non-metastatic LGMS is surgical resection with, where possible, removal of all tumor cells in order to reduce this tumor's recurrence rate (e.g. ~27% and ~38% in two different studies). Following this surgery, individuals should undergo long-term observation to check for post-surgical recurrences and the uncommon instances of metastases. One study suggested that tumor cells with high rates of proliferation, tumors containing areas of necrosis, tumor sizes >10 cm in largest diameters, and deep-seated tumors are at higher risks for metastasizing.
245:(which omentum not defined), heart, eye socket (in an 11 month old infant), and chest wall/breast. While typically presenting as slow growing, painless masses, some individuals have presented with increasingly painful subcutaneous or submucosal masses (16 of 50 individuals reported pain in one retrospective study). Rare cases of submucosal LGMS tumors have presented with more serious symptoms such as partial
136:. WHO, 2020, classifies HGMS (preferred name: undifferentiated pleomorphic sarcoma) as a soft tissue tumor in the category of tumors of uncertain differentiation. This article follows the WHO classification: here, LGMS includes IGMS but not HGMS which is a more aggressive and metastasizing tumor than LGMS and consists of cells of uncertain origin.
478:
The majority of studies on the prognosis of patients treated for LGMS have focused on short-term (i.e. one-year) follow-up times. One study of 49 patients (age range: 29.5–64.5; average age: 46.2 years; median age: 51.0 years) treated for LGFS reported overall survival percentages at 3 and 5 years of
462:
have been used with or without surgical resections to treat cases in which tumor resections were later found to leave tumor cells behind, in which tumors could not be safely resected, and in which metastases were present. In the study of 96 individuals presenting with LGMS tumors for the first time,
426:
of chromosomes 1, 12, and 5 and losses in genetic material on the long (i.e. 'q') arm of chromosome 15. These chromosome abnormalities are considered non-specific. Analysis of LGMS tumor cells for chromosome and gene abnormalities has not yet been helpful in understanding or diagnosing the disorder.
196:
studies. In another study, 103 individuals diagnosed with LGMS were aged 2–75 years (median: 43 years) with 12.6% < 18 years, 65.1% 18–60 years, and 22.3% >60 years old. Eighty-two percent of their LGMS tumors were located in soft tissues (28.2% in mucous membranes, 21.8% in muscle, 19.2% in
435:
LGMS should be suspected in cases presenting as nodular masses composed of spindle-shaped cells combining fibroblast and smooth muscle cell features that are arranged in bundles and express α-smooth muscle actin and/or desmin proteins but not vimentin, S-100, CD34 or other marker proteins cited in
310:
fibers. The tumors are not encapsulated and commonly infiltrate adjacent fibrous, fat, or skeletal muscle tissues. (The tumor's spindle-shaped cells may infiltrate between individual skeletal muscle fibers to create a characteristic checkerboard pattern.) LGMS tissues commonly have small or more
261:
LGMS tumor. A study of 96 individuals presenting for the first time with LGMS found that 51.0% had local disease, 25.0% had regional disease, 15.6% had metastases to the local lymph nodes, and 8.3% had distant metastases. (In the study 103 individuals, the distant metastasis rate was 4.4%.)
183:
LGMS's are commonly treated by surgical removal of the tumor along with all its cells, which if not removed increase the probability that the tumor will recur at the site of its removal. LGMS tumors typically show little or no sensitivity to radiotherapy and chemotherapy treatments.
436:
the previous section. Spindle-shaped cell infiltrations between individual skeletal muscle fibers that form a checkerboard pattern and the presence of foci containing epithelioid, polygonal cells that express cytokeratin and TP63 proteins are also indicative of a LGMS tumor.
179:
bones. They most often develop in middle-aged adults (average: 40 years old) but have been diagnosed in all age-groups. These tumors often recur at the sites of their surgical removal and may metastasize to nearby lymph nodes and distant tissues.
345:
protein found in all muscle forms including smooth muscle) proteins, with some tumors composed of cells expressing both of these proteins and other tumors composed of cells expressing only one of them. The tumor cells often express
116:) by Mentzel et al. in 1998. Myofibroblastic sarcomas had been divided into low-grade myofibroblastic sarcomas, intermediate‐grade myofibroblasic sarcomas, i.e. IGMS, and high‐grade myofibroblasic sarcomas, i.e. HGMS (also termed
1067:
Xu Y, Xu G, Wang X, Mao M, Wu H, Baklaushev VP, Chekhonin VP, Peltzer K, Wang G, Zhang C (February 2021). "Is there a role for chemotherapy and radiation in the treatment of patients with low-grade myofibroblastic sarcoma?".
418:
and/or giant marker chromosome, which commonly occur in the cells of various mesenchymal tumors, were found in one case of LGMS. In addition, these tumor cells may, in rare cases, contain
511:
Yonezawa H, Yamamoto N, Hayashi K, Takeuchi A, Miwa S, Igarashi K, Langit MB, Kimura H, Shimozaki S, Kato T, Morinaga S, Araki Y, Asano Y, Ikeda H, Nojima T, Tsuchiya H (December 2020).
1222:
Tang L, Xu H, Gao H, Yang H, Chen S, Zhang P (November 2020). "Primary low-grade myofibroblastic sarcoma: A rare case report of this tumor in the orbit and literature review".
197:
skin, and 12.9% in other soft tissues) and 18% were in bone. Overall, 51.5% of their tumors were in the head and neck areas (most commonly the tongue, followed by the
108:. As it is currently recognized, LGMS was first described as a rare, atypical myofibroblastic tumor (i.e. a tumor consisting of cells with the microscopic features of
1602:
579:
Mentzel T, Dry S, Katenkamp D, Fletcher CD (October 1998). "Low-grade myofibroblastic sarcoma: analysis of 18 cases in the spectrum of myofibroblastic tumors".
128:, and malignancy features. LGMS and IGMS are now classified together by the World Health Organization (WHO), 2020, in the category of intermediate (rarely
1003:"Low-grade myofibroblastic sarcoma with abdominal pain, a stuffy nose, hearing loss, and multiple cavity effusion: a case report and literature review"
1597:
1364:"Evaluation and Management of an Uncommon Tumor of the Larynx: A Case Report and Literature Review of Laryngeal Low-Grade Myofibroblastic Sarcoma"
133:
117:
1114:
Chan JY, Gooi Z, Wong EW, Ng SK, Tong MC, Vlantis AC (January 2017). "Low-grade myofibroblastic sarcoma: A population-based study".
1552:"Characterization of giant marker and ring chromosomes in a pleomorphic leiomyosarcoma of soft tissue by spectral karyotyping"
1164:"Low-Grade Myofibroblastic Sarcoma of the Oral Cavity: A Report of Three Cases Illustrating an Emerging Disease in Children"
1316:
Oylumlu M, Yildiz A, Ercan S, Oylumlu M, Davutoglu V (2014). "Cardiac metastasis of a low-grade myofibroblastic sarcoma".
815:
Choi JH, Ro JY (January 2021). "The 2020 WHO Classification of Tumors of Soft Tissue: Selected
Changes and New Entities".
205:, face, skull, and ear canal), 25.2% were in the trunk, and 23.3% were in an arm or leg. Bone tumors were located in the
616:"Malignant fibrous histiocytoma of the bone in a traumatic amputation stump: A case report and review of the literature"
302:
LGMS tissues generally show bundles of atypical spindle-shaped cells in a variably hyalinized (i.e. glassy appearing)
45:
419:
160:
342:
513:"Low-grade myofibroblastic sarcoma of the levator scapulae muscle: a case report and literature review"
475:). Further studies are needed to define the usefulness of radiation therapy and chemotherapy in LGMS.
330:
168:
121:
144:
1501:
Magro G, Salvatorelli L, Puzzo L, Piombino E, Bartoloni G, Broggi G, Vecchio GM (December 2019).
1447:
1341:
1247:
1139:
1093:
840:
699:
113:
35:
30:
Intermediate-grade myofibroblastic sarcoma is now regarded as a low-grade myofibroblastic sarcoma
1573:
1532:
1474:
1439:
1395:
1333:
1298:
1239:
1195:
1131:
1085:
1032:
966:
904:
832:
797:
748:
691:
647:
596:
544:
315:-like) cells with a polygonal shape. In a minority of cases, the tumor tissues have scattered
295:
246:
193:
164:
1563:
1522:
1514:
1429:
1385:
1375:
1325:
1288:
1278:
1231:
1185:
1175:
1123:
1077:
1022:
1014:
956:
948:
937:"Soft Tissue Special Issue: Fibroblastic and Myofibroblastic Neoplasms of the Head and Neck"
894:
884:
824:
787:
779:
738:
730:
683:
637:
627:
588:
534:
524:
423:
312:
275:
152:
1607:
415:
303:
271:
238:
234:
125:
1418:"Low-grade myofibroblastic sarcoma of the pancreas: A case report and literature review"
1527:
1502:
1390:
1363:
1293:
1266:
1190:
1163:
1027:
1002:
961:
936:
899:
872:
792:
767:
743:
719:"High-grade myofibroblastic sarcoma of the pleura: A case report and literature review"
718:
642:
615:
539:
512:
242:
1591:
1503:"Practical approach to diagnosis of bland-looking spindle cell lesions of the breast"
1251:
1097:
844:
703:
592:
129:
1451:
1180:
192:
LGMS present as single tumors that ranged in size from 0.4 to 24.0 cm in three
1345:
1143:
459:
455:
449:
445:
359:
51:
387:
299:
253:
due to a LGMS tumor in the heart, difficulty in swallowing and breathing due to a
1162:
Jayasooriya PR, Athukorala C, Attygalla M, Mendis BR, Lombardi T (January 2021).
828:
468:
395:
379:
283:
250:
230:
222:
1081:
952:
529:
262:
Metastasis have been reported to develop in various sites including the lungs,
1283:
873:"Limbal, low-grade myofibroblastic sarcoma: Case report and literature review"
687:
632:
472:
464:
411:
383:
320:
316:
279:
267:
109:
1518:
1434:
1417:
1267:"Giant low-grade primary myofibroblastic sarcoma of the posterior chest wall"
1235:
1018:
889:
734:
82:
1577:
1536:
1443:
1399:
1337:
1302:
1243:
1199:
1135:
1089:
1036:
970:
908:
836:
801:
783:
768:"The 2020 WHO Classification of Soft Tissue Tumours: news and perspectives"
752:
695:
651:
548:
1478:
600:
333:
analyses find that the LGMS tumors' spindle-shaped cells commonly express
1568:
1551:
1380:
391:
347:
324:
307:
258:
210:
202:
414:
abnormalities have been found in the tumor cells of a few LGMS cases. A
1329:
1127:
351:
214:
105:
338:
263:
254:
226:
198:
156:
354:(also termed INI-1 and SNF5) proteins but typically fail to express
1362:
Nair NP, Kaushal D, Rao M, Soni K, Vaithankalath S (October 2020).
367:
334:
218:
206:
1550:
Nishio J, Aoki M, Nabeshima K, Iwasaki H, Naito M (August 2012).
399:
375:
371:
363:
355:
120:
and pleomorphic myofibrosarcoma ) based on their microscopic
139:
LGMS tumors are typically painless lesions that develop in:
1001:
Wu X, Guo L, Li S, Zheng Y, Fan B, Zhou C (January 2020).
394:
proteins. The epithelioid, polygonal-shaped cells express
249:
due to intrabdominal LGMS tumors, shortness of breath and
717:
Zhao R, Wang J, Zhang H, Chi Y, Bi N (October 2020).
91:
81:
73:
65:
57:
44:
34:
26:
21:
766:Sbaraglia M, Bellan E, Dei Tos AP (April 2021).
614:Zhao KY, Yan X, Yao PF, Mei J (September 2021).
1496:
1494:
1492:
1490:
1488:
1411:
1409:
1357:
1355:
1217:
1215:
1213:
1211:
1209:
1157:
1155:
1153:
1109:
1107:
1062:
1060:
1058:
1056:
1054:
1052:
1050:
1048:
1046:
996:
994:
992:
990:
988:
986:
984:
982:
980:
229:. In other reports, the tumors occurred in the
930:
928:
926:
924:
922:
920:
918:
866:
864:
862:
860:
858:
856:
854:
674:Fisher C (September 2004). "Myofibrosarcoma".
669:
667:
665:
663:
661:
506:
504:
502:
500:
498:
496:
494:
492:
1416:Peng L, Tu Y, Li Y, Xiao W (September 2018).
1007:The Journal of International Medical Research
574:
572:
570:
568:
566:
564:
562:
560:
558:
444:Past treatments for LGMS, including surgery,
422:such as gains in the genetic material on the
8:
871:Mulay K, Sen M, Honavar SG (November 2020).
1422:Journal of Cancer Research and Therapeutics
581:The American Journal of Surgical Pathology
18:
1567:
1526:
1433:
1389:
1379:
1292:
1282:
1189:
1179:
1026:
960:
898:
888:
791:
742:
641:
631:
538:
528:
257:LGMS tumor, and abdominal pain due to a
147:, i.e. the lowermost layer of the skin;
488:
337:(also known α-smooth muscle actin) and
134:fibroblastic and myofibroblastic tumors
50:Post-surgical recurrences; uncommonly
1465:Lehoczky T, Halasy M (May 1966). "".
1070:Clinical & Translational Oncology
104:(LGMS) is a subtype of the malignant
7:
1603:Connective and soft tissue neoplasms
1318:Echocardiography (Mount Kisco, N.Y.)
935:Baranov E, Hornick JL (March 2020).
311:extensive foci of epithelioid (i.e.
118:undifferentiated pleomorphic sarcoma
1271:World Journal of Surgical Oncology
1265:Katalinic D, Santek F (May 2017).
159:that line passageways such as the
151:submucosa, i.e. the thin layer of
14:
1224:European Journal of Ophthalmology
406:Chromosome and gene abnormalities
102:Low-grade myofibroblastic sarcoma
22:Low-grade myofibroblastic sarcoma
593:10.1097/00000478-199810000-00008
1598:Dermal and subcutaneous growths
1181:10.3390/dermatopathology8010001
877:Indian Journal of Ophthalmology
620:World Journal of Clinical Cases
817:Advances in Anatomic Pathology
1:
517:BMC Musculoskeletal Disorders
300:hematoxylin and eosin stained
829:10.1097/PAP.0000000000000284
327:(i.e. dead or dying cells).
1624:
1082:10.1007/s12094-020-02425-4
953:10.1007/s12105-019-01104-3
530:10.1186/s12891-020-03857-3
221:, or in one case each the
1428:(Supplement): S796–S799.
1284:10.1186/s12957-017-1167-7
688:10.1007/s00428-004-1038-9
633:10.12998/wjcc.v9.i26.7930
77:Surgical removal of tumor
1519:10.32074/1591-951X-31-19
1435:10.4103/0973-1482.183551
1236:10.1177/1120672120970392
1019:10.1177/0300060519895661
40:Tumor, sometimes painful
941:Head and Neck Pathology
890:10.4103/ijo.IJO_2410_20
735:10.1111/1759-7714.13613
440:Treatment and prognosis
1013:(1): 300060519895661.
784:10.32074/1591-951X-213
420:copy number variations
306:background containing
343:intermediate filament
155:lying just below the
1569:10.3892/or.2012.1835
1381:10.7759/cureus.11072
424:short (i.e. 'p') arm
319:, sites of numerous
282:, heart, brain, and
145:subcutaneous tissues
331:Immunohistochemical
114:smooth muscle cells
1330:10.1111/echo.12370
1128:10.1002/lary.26146
247:bowel obstructions
883:(11): 2538–2540.
729:(10): 3011–3014.
626:(26): 7930–7936.
296:histopathological
194:literature review
99:
98:
16:Medical condition
1615:
1582:
1581:
1571:
1556:Oncology Reports
1547:
1541:
1540:
1530:
1498:
1483:
1482:
1469:(in Hungarian).
1462:
1456:
1455:
1437:
1413:
1404:
1403:
1393:
1383:
1359:
1350:
1349:
1313:
1307:
1306:
1296:
1286:
1262:
1256:
1255:
1230:(2): NP67–NP70.
1219:
1204:
1203:
1193:
1183:
1168:Dermatopathology
1159:
1148:
1147:
1116:The Laryngoscope
1111:
1102:
1101:
1064:
1041:
1040:
1030:
998:
975:
974:
964:
932:
913:
912:
902:
892:
868:
849:
848:
812:
806:
805:
795:
763:
757:
756:
746:
714:
708:
707:
671:
656:
655:
645:
635:
611:
605:
604:
576:
553:
552:
542:
532:
508:
276:abdominal cavity
161:gastrointestinal
157:mucous membranes
126:immunophenotypic
19:
1623:
1622:
1618:
1617:
1616:
1614:
1613:
1612:
1588:
1587:
1586:
1585:
1549:
1548:
1544:
1500:
1499:
1486:
1464:
1463:
1459:
1415:
1414:
1407:
1361:
1360:
1353:
1315:
1314:
1310:
1264:
1263:
1259:
1221:
1220:
1207:
1161:
1160:
1151:
1113:
1112:
1105:
1066:
1065:
1044:
1000:
999:
978:
934:
933:
916:
870:
869:
852:
814:
813:
809:
765:
764:
760:
723:Thoracic Cancer
716:
715:
711:
676:Virchows Archiv
673:
672:
659:
613:
612:
608:
587:(10): 1228–38.
578:
577:
556:
510:
509:
490:
485:
442:
433:
416:ring chromosome
408:
323:, and areas of
292:
272:thoracic cavity
239:greater omentum
235:small intestine
190:
17:
12:
11:
5:
1621:
1619:
1611:
1610:
1605:
1600:
1590:
1589:
1584:
1583:
1542:
1513:(4): 344–360.
1484:
1473:(18): 819–23.
1467:Orvosi Hetilap
1457:
1405:
1374:(10): e11072.
1351:
1308:
1257:
1205:
1149:
1122:(1): 116–121.
1103:
1076:(2): 344–352.
1042:
976:
914:
850:
807:
758:
709:
657:
606:
554:
487:
486:
484:
481:
441:
438:
432:
429:
407:
404:
291:
288:
243:lesser omentum
233:, lip, groin,
189:
186:
97:
96:
93:
89:
88:
85:
79:
78:
75:
71:
70:
67:
63:
62:
59:
55:
54:
48:
42:
41:
38:
32:
31:
28:
24:
23:
15:
13:
10:
9:
6:
4:
3:
2:
1620:
1609:
1606:
1604:
1601:
1599:
1596:
1595:
1593:
1579:
1575:
1570:
1565:
1561:
1557:
1553:
1546:
1543:
1538:
1534:
1529:
1524:
1520:
1516:
1512:
1508:
1504:
1497:
1495:
1493:
1491:
1489:
1485:
1480:
1476:
1472:
1468:
1461:
1458:
1453:
1449:
1445:
1441:
1436:
1431:
1427:
1423:
1419:
1412:
1410:
1406:
1401:
1397:
1392:
1387:
1382:
1377:
1373:
1369:
1365:
1358:
1356:
1352:
1347:
1343:
1339:
1335:
1331:
1327:
1323:
1319:
1312:
1309:
1304:
1300:
1295:
1290:
1285:
1280:
1276:
1272:
1268:
1261:
1258:
1253:
1249:
1245:
1241:
1237:
1233:
1229:
1225:
1218:
1216:
1214:
1212:
1210:
1206:
1201:
1197:
1192:
1187:
1182:
1177:
1173:
1169:
1165:
1158:
1156:
1154:
1150:
1145:
1141:
1137:
1133:
1129:
1125:
1121:
1117:
1110:
1108:
1104:
1099:
1095:
1091:
1087:
1083:
1079:
1075:
1071:
1063:
1061:
1059:
1057:
1055:
1053:
1051:
1049:
1047:
1043:
1038:
1034:
1029:
1024:
1020:
1016:
1012:
1008:
1004:
997:
995:
993:
991:
989:
987:
985:
983:
981:
977:
972:
968:
963:
958:
954:
950:
946:
942:
938:
931:
929:
927:
925:
923:
921:
919:
915:
910:
906:
901:
896:
891:
886:
882:
878:
874:
867:
865:
863:
861:
859:
857:
855:
851:
846:
842:
838:
834:
830:
826:
822:
818:
811:
808:
803:
799:
794:
789:
785:
781:
777:
773:
769:
762:
759:
754:
750:
745:
740:
736:
732:
728:
724:
720:
713:
710:
705:
701:
697:
693:
689:
685:
682:(3): 215–23.
681:
677:
670:
668:
666:
664:
662:
658:
653:
649:
644:
639:
634:
629:
625:
621:
617:
610:
607:
602:
598:
594:
590:
586:
582:
575:
573:
571:
569:
567:
565:
563:
561:
559:
555:
550:
546:
541:
536:
531:
526:
522:
518:
514:
507:
505:
503:
501:
499:
497:
495:
493:
489:
482:
480:
476:
474:
470:
466:
461:
457:
453:
451:
447:
439:
437:
430:
428:
425:
421:
417:
413:
405:
403:
401:
397:
393:
389:
385:
381:
377:
373:
369:
365:
361:
357:
353:
349:
344:
340:
336:
332:
328:
326:
322:
318:
314:
309:
305:
301:
297:
289:
287:
285:
281:
277:
273:
269:
265:
260:
256:
252:
248:
244:
240:
236:
232:
228:
224:
220:
216:
212:
208:
204:
200:
195:
187:
185:
181:
178:
175:muscles; and
174:
170:
169:genitourinary
166:
162:
158:
154:
150:
146:
142:
137:
135:
131:
130:metastasizing
127:
123:
122:morphological
119:
115:
111:
107:
103:
94:
90:
86:
84:
80:
76:
72:
68:
64:
60:
56:
53:
49:
47:
46:Complications
43:
39:
37:
33:
29:
25:
20:
1562:(2): 533–8.
1559:
1555:
1545:
1510:
1506:
1470:
1466:
1460:
1425:
1421:
1371:
1367:
1321:
1317:
1311:
1274:
1270:
1260:
1227:
1223:
1171:
1167:
1119:
1115:
1073:
1069:
1010:
1006:
947:(1): 43–58.
944:
940:
880:
876:
823:(1): 44–58.
820:
816:
810:
778:(2): 70–84.
775:
771:
761:
726:
722:
712:
679:
675:
623:
619:
609:
584:
580:
520:
516:
477:
460:chemotherapy
456:Radiotherapy
454:
450:chemotherapy
446:radiotherapy
443:
434:
409:
329:
298:analyses of
294:Microscopic
293:
251:palpitations
191:
188:Presentation
182:
176:
172:
148:
140:
138:
101:
100:
52:metastasizes
1507:Pathologica
1324:(1): E1–4.
772:Pathologica
469:pirarubicin
396:cytokeratin
380:cytokeratin
321:neutrophils
284:spinal cord
268:lymph nodes
231:oral mucosa
223:hard palate
165:respiratory
110:fibroblasts
58:Usual onset
27:Other names
1592:Categories
1174:(1): 1–9.
523:(1): 836.
483:References
473:nedaplatin
465:ifosfamide
412:chromosome
402:proteins.
317:mast cells
313:epithelial
280:peritoneum
1277:(1): 96.
1252:226988997
1098:220286531
845:221862064
704:220565385
431:Diagnosis
388:β-catenin
341:(i.e. an
290:Pathology
270:, bones,
255:laryngeal
83:Prognosis
74:Treatment
1578:22641359
1537:31965112
1452:52814348
1444:30249907
1400:33224666
1338:24111760
1303:28468630
1244:33198493
1200:33401376
1136:27377169
1090:32607812
1037:31975633
971:31950474
909:33120683
837:32960834
802:33179614
753:32815307
696:15173943
652:34621848
549:33302922
410:Various
392:myogenin
348:vimentin
325:necrosis
308:collagen
259:pancreas
211:mandible
203:mandible
201:, gums,
171:tracts;
106:sarcomas
95:Uncommon
61:All ages
36:Symptoms
1528:8145669
1479:5328880
1391:7676948
1346:7195357
1294:5415824
1191:7838777
1144:9627754
1028:7114293
962:7021862
900:7774147
793:8167394
744:7529570
643:8462244
601:9777985
540:7731512
352:SMARCB1
304:stromal
215:maxilla
87:Guarded
69:Unknown
1608:Cancer
1576:
1535:
1525:
1477:
1450:
1442:
1398:
1388:
1368:Cureus
1344:
1336:
1301:
1291:
1250:
1242:
1198:
1188:
1142:
1134:
1096:
1088:
1035:
1025:
969:
959:
907:
897:
843:
835:
800:
790:
751:
741:
702:
694:
650:
640:
599:
547:
537:
471:, and
448:, and
339:desmin
264:pleura
227:sacrum
219:tibias
207:femurs
199:larynx
153:tissue
92:Deaths
66:Causes
1448:S2CID
1342:S2CID
1248:S2CID
1140:S2CID
1094:S2CID
841:S2CID
700:S2CID
390:, or
368:STAT6
360:S-100
335:ACTA2
1574:PMID
1533:PMID
1475:PMID
1440:PMID
1396:PMID
1334:PMID
1299:PMID
1240:PMID
1196:PMID
1132:PMID
1086:PMID
1033:PMID
967:PMID
905:PMID
833:PMID
798:PMID
749:PMID
692:PMID
648:PMID
597:PMID
545:PMID
458:and
400:TP63
398:and
376:CD56
372:CD68
364:CD34
356:CD34
350:and
225:and
143:the
112:and
1564:doi
1523:PMC
1515:doi
1511:111
1471:107
1430:doi
1386:PMC
1376:doi
1326:doi
1289:PMC
1279:doi
1232:doi
1186:PMC
1176:doi
1124:doi
1120:127
1078:doi
1023:PMC
1015:doi
957:PMC
949:doi
895:PMC
885:doi
825:doi
788:PMC
780:doi
776:113
739:PMC
731:doi
684:doi
680:445
638:PMC
628:doi
589:doi
535:PMC
525:doi
384:ERG
241:or
124:,
1594::
1572:.
1560:28
1558:.
1554:.
1531:.
1521:.
1509:.
1505:.
1487:^
1446:.
1438:.
1426:14
1424:.
1420:.
1408:^
1394:.
1384:.
1372:12
1370:.
1366:.
1354:^
1340:.
1332:.
1322:31
1320:.
1297:.
1287:.
1275:15
1273:.
1269:.
1246:.
1238:.
1228:32
1226:.
1208:^
1194:.
1184:.
1170:.
1166:.
1152:^
1138:.
1130:.
1118:.
1106:^
1092:.
1084:.
1074:23
1072:.
1045:^
1031:.
1021:.
1011:48
1009:.
1005:.
979:^
965:.
955:.
945:14
943:.
939:.
917:^
903:.
893:.
881:68
879:.
875:.
853:^
839:.
831:.
821:28
819:.
796:.
786:.
774:.
770:.
747:.
737:.
727:11
725:.
721:.
698:.
690:.
678:.
660:^
646:.
636:.
622:.
618:.
595:.
585:22
583:.
557:^
543:.
533:.
521:21
519:.
515:.
491:^
467:,
386:,
382:,
378:,
374:,
370:,
366:,
362:,
358:,
286:.
278:,
274:,
266:,
237:,
217:,
213:,
209:,
177:4)
173:3)
167:,
163:,
149:2)
141:1)
132:)
1580:.
1566::
1539:.
1517::
1481:.
1454:.
1432::
1402:.
1378::
1348:.
1328::
1305:.
1281::
1254:.
1234::
1202:.
1178::
1172:8
1146:.
1126::
1100:.
1080::
1039:.
1017::
973:.
951::
911:.
887::
847:.
827::
804:.
782::
755:.
733::
706:.
686::
654:.
630::
624:9
603:.
591::
551:.
527::
Text is available under the Creative Commons Attribution-ShareAlike License. Additional terms may apply.